Clinical trial · Observational
Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness
NCT01667952CI-TRIAL-00086887completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to establish a registry of survivors of cancer, tumor, or a related illness.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pediatric or Young Adult Cancer Survivors | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Other | — | UNRESOLVED |
| Family History Questionnaire (FHQ) | Genetic | — | UNRESOLVED |
| Salvia sample | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer Survivors
- description
- The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
- interventionNames
- Genetic: Family History Questionnaire (FHQ)
- Genetic: Salvia sample
- Other: Blood sample
Primary outcomes (1)
- measure
- establish a registry of DNA
- timeFrame
- 4 years
- description
- For the purpose of facilitating future genetic laboratory investigations of late effects among of survivors of cancer, tumors, or a related illness. Patients in the ALTFU Program are followed for secondary malignant neoplasms and other adverse outcomes (so-called "late effects") including cardiomyopathy, pulmonary fibrosis, cardiac valvular pathology, osteoporosis, and others. The following data will be ascertained from each study participant: (1) family history information will be ascertained using the Family History Questionnaire (Appendix A); and (2) saliva or blood samples for genetic analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * English speaking * A personal history of cancer tumor, or a related illness * Followed in the the Adult Long Term Follow Up Program, Pediatric Long Term Follow Up Program, or Lymphoma Service at MSKCC Exclusion Criteria: * Evidence of active progression of disease or recurrence * Neurocognitive deficits that impair ability to give informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.